Biogen Inc vs HCA Health Inc — how do they compare? Biogen Inc trades at $204.59 (market cap $30.13B), while HCA Health Inc trades at $409.89 (market cap $89.08B). The key difference: HCA Health Inc is far larger — about 3× Biogen Inc's market cap, and HCA Health Inc pays a 0.76% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | HCA | |
|---|---|---|
Market Cap | $30.13B | $89.08B |
Sector | Health | Health |
52-Week High | $216.63 | $545.13 |
52-Week Low | $128.93 | $361.32 |
Enterprise Value | $37.20B | $139.62B |
Dividend Yield | — | 0.76% |
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
HCA Healthcare trades at $414.03, up 0.16% today, with strong technical momentum as price sits above key support levels. The company demonstrates solid fundamentals with Q2 2026 earnings beating estimates, revenue growth to $75.6B in 2025, and consistent dividend payments. Recent management appointments signal strategic focus on clinical operations and ambulatory services.
HCA presents a compelling investment case with attractive valuation (P/E 13.8), analyst consensus price target of $449.93 (8.7% upside), and strong institutional support. However, risks include ongoing legal investigations, rising expenses impacting margins, and high debt levels at 80.9% debt-to-asset ratio that could constrain financial flexibility.
Trailing returns across standard periods
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →